Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Neoplasms, Nausea
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron 0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and vomiting induced by moderately emetogenic…
- Conditions
- Neoplasms, Nausea, Vomiting
- Trial name
- NCT00687011
- Testing
- Palonosetron and Dexamethasone
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two antiemetic drugs, both given with oral dexamethasone.
- Trial name
- NCT01376297
- Testing
- Netupitant and Palonosetron, Aprepitant, Palonosetron
- Where
- 75 sites in United States, Bulgaria and 8 more
- Volunteers
- 413 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting, Prophylaxis
Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of palonosetron after intravenous administration of palonosetron in healthy volunteers under fasting conditions.
- Trial name
- NCT04585412
- Testing
- Palonosetron
- Where
- Taiwan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Chemotherapy-Induced Nausea and Vomiting
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
- Trial name
- NCT00818259
- Testing
- Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron
- Volunteers
- 92 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting (CINV)
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
This study is Phase 2 pharmacokinetic (PK) and pharmacodynamic (PD) dose-finding study of oral netupitant administered concomitantly with oral palonosetron in pediatric cancer patients for the prevention of nausea and vomiting…
- Trial name
- CINV (NCT03204279)
- Testing
- Netupitant, Palonosetron
- Where
- 17 sites in United States, Russia and 2 more
- Volunteers
- 67 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy Induced Nausea and Vomiting
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring…
- Trial name
- NCT00642512
- Testing
- dronabinol, ondansetron, dronabinol/ondansetron
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- Solvay Pharmaceuticals
Chemotherapy-induced Nausea and Vomiting
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving HEC.
- Trial name
- NCT01499849
- Testing
- Rolapitant, Granisetron, dexamethasone
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Tesaro, Inc.
Nausea, Vomiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07169851
- Testing
- LY3537021, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Nausea and Vomiting, Chemotherapy-Induced
The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V.
- Trial name
- NCT00440128
- Testing
- Docetaxel, Casopitant/Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Chemotherapy-Induced
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
Ondansetron, also known as Zofran, is a marketed compound used for the prevention of nausea and vomiting. This study, called a thorough QT study, will characterize the effects of a single intravenous (IV) dose of ondansetron on…
- Trial name
- NCT01449188
- Testing
- ondansetron, moxifloxacin, saline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Chemotherapy-Induced
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and…
- Trial name
- NCT00404378
- Testing
- ketoconazole, casopitant 100 mg, Casopitant 50 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Chemotherapy-Induced
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.
- Trial name
- NCT00405080
- Testing
- GW679769 (Casopitant) oral tablets, Rifampin oral capsules
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Chemotherapy-Induced
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
This A Three-Part Drug-Drug Interaction Study To Evaluate Effects of Casopitant On Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adults
- Trial name
- NCT00511823
- Testing
- casopitant, dolasetron, granisetron
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Efficacy, Safety
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients
- Conditions
- Efficacy, Safety, Megestrol Acetate, Adult Subject
- Trial name
- NCT07130617
- Testing
- Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, High dose of Megestrol Acetate Oral Suspension combined with standard therapy
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of…
- Trial name
- NCT00104403
- Testing
- GW679769, Dexamethasone, Ondansetron Hydrochloride
- Where
- 113 sites in United States, Argentina and 22 more
- Volunteers
- 722 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
- Trial name
- EASE (NCT00619359)
- Testing
- Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone
- Volunteers
- 2,322 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.
- Trial name
- NCT05509634
- Testing
- HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
- Where
- China
- Volunteers
- 754 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd